Metformin Reduces the Progression of Atherogenesis by Regulating Sestrin2-mTOR Pathway in Obese and Diabetic Rats
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventing atherosclerosis and cardiac outcomes is unclear. Hence, we aimed to assess the effect of metformin on preventing atherosclerosis and its regulatory role in the Sestrin2-AMPK -mTOR pathway in obese/diabetic rats. Methods: Animals were fed a high-fat diet to induce obesity, administered streptozotocin to induce diabetes, and then treated with metformin (150 mg/kg body weight) for 14 weeks. Aorta and heart tissues were analyzed for Sestrin2 status by western blotting and immunohistochemistry, AMPK and mTOR activities were investigated using western blotting, and atherogenicity-related events were evaluated using reverse transcription quantitative polymerase chain reaction and histology. Results: Obese and diabetic rats showed significant decrease in Sestrin2 levels and AMPK activity, accompanied by increased mTOR activity in the heart and aorta tissues. Metformin treatment significantly restored Sestrin2 and AMPK levels, reduced mTOR activity, and restored the altered expression of inflammatory markers and adhesion molecules in obese and diabetic rats to normal levels. A histological analysis of samples from obese and diabetic rats showed atherosclerotic lesions both in aorta and heart tissues. The metformin-treated rats showed a decrease in atherosclerotic lesions, cardiac hypertrophy, and cardiomyocyte degeneration. Conclusion: This study presents further insights into the beneficial effects of metformin and its protective role against atherosclerosis through regulation of the Sestrin2-AMPK-mTOR pathway.
Abstract
Objective: In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventing atherosclerosis and cardiac outcomes is unclear. Hence, we aimed to assess the effect of metformin on preventing atherosclerosis and its regulatory role in the Sestrin2-AMPK -mTOR pathway in obese/diabetic rats. Methods: Animals were fed a high-fat diet to induce obesity, administered streptozotocin to induce diabetes, and then treated with metformin (150 mg/kg body weight) for 14 weeks. Aorta and heart tissues were analyzed for Sestrin2 status by western blotting and immunohistochemistry, AMPK and mTOR activities were investigated using western blotting, and atherogenicity-related events were evaluated using reverse transcription quantitative polymerase chain reaction and histology. Results: Obese and diabetic rats showed significant decrease in Sestrin2 levels and AMPK activity, accompanied by increased mTOR activity in the heart and aorta tissues. Metformin treatment significantly restored Sestrin2 and AMPK levels, reduced mTOR activity, and restored the altered expression of inflammatory markers and adhesion molecules in obese and diabetic rats to normal levels. A histological analysis of samples from obese and diabetic rats showed atherosclerotic lesions both in aorta and heart tissues. The metformin-treated rats showed a decrease in atherosclerotic lesions, cardiac hypertrophy, and cardiomyocyte degeneration. Conclusion: This study presents further insights into the beneficial effects of metformin and its protective role against atherosclerosis through regulation of the Sestrin2-AMPK-mTOR pathway.
참고문헌 (22)
- Cornier MA, "The metabolic syndrome", Endocr Rev, 29, pp.777~822 (2008)
- Kassi E, "Metabolic syndrome : definitions and controversies", BMC Med, 9, pp.48~ (2011)
- "Obesity and overweight"[URL]
- Katakami N, "Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus", J Atheroscler Thromb, 25, pp.27~39 (2018)
- Libby P, "Atherosclerosis", Nat Rev Dis Primers, 5, pp.56~ (2019)
- Sundararajan S, "Sestrin2 regulates monocyte activation through AMPK-mTOR nexus under high-glucose and dyslipidemic conditions", J Cell Biochem, 120, pp.8201~8213 (2019)
- Sundararajan S, "Decreased Sestrin levels in patients with type 2 diabetes and dyslipidemia and their association with the severity of atherogenic index", J Endocrinol Invest, 44, pp.1395~1405 (2021)
- Luo F, "Metformin in patients with and without diabetes : a paradigm shift in cardiovascular disease management", Cardiovasc Diabetol, 18, pp.54~ (2019)
- Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action", J Clin Invest, 108, pp.1167~1174 (2001)
- Balakumar M, "Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL", 6J mice, 2018, pp.57, 279~295
- Holman RR, "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359, pp.1577~1589 (2008)
- Yanovski JA, "Effects of metformin on body weight and body composition in obese insulin-resistant children : a randomized clinical trial", Diabetes, 60, pp.477~485 (2011)
- Ormazabal V, "Association between insulin resistance and the development of cardiovascular disease", Cardiovasc Diabetol, 17, pp.122~ (2018)
- Lin SH, "Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus : a cohort study", PeerJ, 6, pp.e4578~ (2018)
- Kashi Z, "The role of metformin response in lipid metabolism in patients with recent-onset type 2 diabetes : HbA1c level as a criterion for designating patients as responders or nonresponders to metformin", PLoS One, 11, pp.e0151543~ (2016)
- Zang M, "AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells", J Biol Chem, 279, pp.47898~47905 (2004)
- Li J, "Effects of metformin in experimental stroke", Stroke, 41, pp.2645~2652 (2010)
- Srivastava RA, "AMP-activated protein kinase : an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases", J Lipid Res, 53, pp.2490~2514 (2012)
- Schwartz CJ, "Atherosclerosis. Potential targets for stabilization and regression", Circulation, 86(Suppl), pp.III117~III123 (1992)[DOI]
- Jiao Y, "mTOR(Mechanistic Target of Rapamycin)inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice", Arterioscler Thromb Vasc Biol, 37, pp.1657~1666 (2017)
- Asai A, "Metformin attenuates early-stage atherosclerosis in mildly hyperglycemic oikawa-nagao mice", J Atheroscler Thromb, 26, pp.1075~1083 (2019)
- Wang Q, "Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission", Diabetes, 66, pp.193~205 (2017)